カテゴリ： GlobalData, ドイツ, 企業調査

MediGene AG (MDG1)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：MediGene AG (MDG1) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9824
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：74
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.

MediGene AG (MDG1) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MediGene AG, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For US$18 Million 13
Partnerships 14
Structured Immunity and Medigene Enter into Research Agreement 14
MediGene Enters into Research Agreement with RXi Pharma 15
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16
Medigene Enters into Agreement with University of Lausanne 17
PharmaDerm and MediGene Enter into Agreement with Women’s Choice Pharma 18
Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20
Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21
MediGene Enters Into Co-Development Agreement For EndoTAG-1 22
MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24
Licensing Agreements 25
2A Pharma Enters into Licensing Agreement with MediGene 25
MediGene Expands Licensing Agreement with bluebird bio 26
Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30
MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31
Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33
Equity Offering 34
Medigene Raises USD37.9 Million in Private Placement of Shares 34
Medigene to Raise USD18.8 Million in Private Placement of Shares 35
Medigene Raises USD22.6 Million in Private Placement of Shares 37
Medigene Raises USD52 Million in Rights Offering of Shares 38
Medigene Raises USD20.3 Million in Rights Offering of Securities 40
Asset Transactions 41
Fougera Pharma Acquires US Rights to Veregen from Medigene 41
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42
Acquisition 43
Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43
Medigene Sells Minority Stake in Immunocore 44
Amgen to Acquire Catherex from Medigene 45
Medigene Acquires Trianta Immunotherapies 46
MediGene AG – Key Competitors 47
MediGene AG – Key Employees 48
MediGene AG – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
May 09, 2018: Medigene reports First Quarter 2018 financials and provides operational update 50
Mar 22, 2018: Medigene publishes 2017 annual report 52
Nov 09, 2017: Medigene Reports Nine Months’ Results 2017 55
Aug 03, 2017: Medigene Reports Results of First Six Months 2017 57
May 11, 2017: Medigene Reports Results Of First Quarter 2017 58
Mar 23, 2017: Medigene publishes its 2016 annual report and outlook for 2017 60
Corporate Communications 62
Sep 03, 2018: Medi­gene an­nounces change in ex­ec­ut­ive lead­er­ship team 62
Apr 11, 2018: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO 63
Aug 08, 2017: Medigene announces formation of new Scientific Advisory Board 64
May 11, 2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role 65
Product News 66
08/30/2017: Medigene Presents Automated Platform For Tcr Identification At Car-Tcr Summit 66
08/28/2017: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy 67
08/25/2017: Medigene Announces Participation At Five Upcoming Scientific And Investor Conferences 69
08/16/2017: Medigene Presents Posters on Immunotherapies at CRI-CIMT-EATI-AACR Conference 70
06/08/2017: Medigene and Academic Partners Publish a Method to Enhance Adoptive T-cell Therapies 71
04/04/2017: Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 72
03/23/2017: Medigene: Announces target and outlines design for its first clinical trial in TCR cancer immunotherapy 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
MediGene AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Deals By Therapy Area, 2012 to YTD 2018 10
MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For US$18 Million 13
Structured Immunity and Medigene Enter into Research Agreement 14
MediGene Enters into Research Agreement with RXi Pharma 15
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16
Medigene Enters into Agreement with University of Lausanne 17
PharmaDerm and MediGene Enter into Agreement with Women’s Choice Pharma 18
Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20
Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21
MediGene Enters Into Co-Development Agreement For EndoTAG-1 22
MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24
2A Pharma Enters into Licensing Agreement with MediGene 25
MediGene Expands Licensing Agreement with bluebird bio 26
Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30
MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31
Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33
Medigene Raises USD37.9 Million in Private Placement of Shares 34
Medigene to Raise USD18.8 Million in Private Placement of Shares 35
Medigene Raises USD22.6 Million in Private Placement of Shares 37
Medigene Raises USD52 Million in Rights Offering of Shares 38
Medigene Raises USD20.3 Million in Rights Offering of Securities 40
Fougera Pharma Acquires US Rights to Veregen from Medigene 41
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42
Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43
Medigene Sells Minority Stake in Immunocore 44
Amgen to Acquire Catherex from Medigene 45
Medigene Acquires Trianta Immunotherapies 46
MediGene AG, Key Competitors 47
MediGene AG, Key Employees 48
MediGene AG, Subsidiaries 49

List of Figures
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

★海外企業調査レポート[MediGene AG (MDG1)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • C-TRI Co Ltd (047920)：製薬・医療：M&Aディール及び事業提携情報
    Summary C-TRI Co Ltd (C-TRI), a subsidiary of DAE HWA Pharmaceutical Co Ltd, is a pharmaceutical company that offers development of new peptide drugs. The company’s products include ethicals, over-the-counter drugs, Quasi-drugs, cosmetics, amendments, pharmaceuticals, taltirelin, desmopressin, presc …
  • China Construction Bank Corp：企業の戦略・SWOT・財務分析
    China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report Summary China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Credit Agricole CIB SA：企業の戦略的SWOT分析
    Credit Agricole CIB SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Endo Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析
    Summary Endo Pharmaceuticals Inc (Endo Pharmaceuticals), a subsidiary of Endo International plc is a healthcare products provider that offers medicinal products. The company manufactures and distributes generic pharmaceutical products and over-the-counter medications. Its products include testostero …
  • Okinawa Cellular Telephone Company (9436)：企業の財務・戦略的SWOT分析
    Okinawa Cellular Telephone Company (9436) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Nichols plc：戦略・SWOT・企業財務分析
    Nichols plc - Strategy, SWOT and Corporate Finance Report Summary Nichols plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Guangzhou Boji Medical & Biotechnological Co Ltd (300404)：製薬・医療：M&Aディール及び事業提携情報
    Summary Guangzhou Boji Medical & Biotechnological Co Ltd (BOJI) is a contract research organization. The organization provides services including regulatory affairs, preclinical research, clinical trials I-IV, PMS, clinical trial for medical devices, post marketing studies (PMS), data management and …
  • Community Health Systems Inc (CYH)：製薬・医療：M&Aディール及び事業提携情報
    Summary Community Health Systems Inc. (CHS) is an operator of general acute care hospitals and outpatient facilities in communities. The company’s services include general acute care services, emergency room services, general and specialty surgery, critical care, internal medicine, obstetrics and di …
  • Alliance Data Systems Corp (ADS)：企業の財務・戦略的SWOT分析
    Alliance Data Systems Corp (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Qenos Pty Ltd：企業の戦略的SWOT分析
    Qenos Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Therapeutic Solutions International Inc (TSOI)：製薬・医療：M&Aディール及び事業提携情報
    Summary Therapeutic Solutions International Inc (Therapeutic Solutions) is a pharmaceutical company that offers supplements. The company offers products such as DermalStilbene, NanoStilbene and ProJuvenol. Its ProJuvenol consists of anti-aging ingredients which helps for a healthy functionality for …
  • Seagate Technology Public Limited Company (STX)：企業の財務・戦略的SWOT分析
    Seagate Technology Public Limited Company (STX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Aurigene Discovery Technologies Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Aurigene Discovery Technologies Ltd (Aurigene), a subsidiary of Dr. Reddy's Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns inte …
  • Metgasco Ltd (MEL)：石油・ガス：M&Aディール及び事業提携情報
    Summary Metgasco Ltd (Metgasco) is an oil and gas exploration company. The company that acquires, explores, produces, and develops oil and gas, petroleum and hydrocarbon assets. It holds interests in Clarence Moreton Basin, an exploration license located in northern New South Wales. Metgasco supplie …
  • Holland Colours NV (HOLCO)：企業の財務・戦略的SWOT分析
    Holland Colours NV (HOLCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Orbis S.A.：企業の戦略・SWOT・財務情報
    Orbis S.A. - Strategy, SWOT and Corporate Finance Report Summary Orbis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Shin-Etsu Chemical Co Ltd (4063)：企業の財務・戦略的SWOT分析
    Shin-Etsu Chemical Co Ltd (4063) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Synlogic Inc (SYBX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Synlogic Inc (Synlogic), formerly TMC Therapeutics Inc is a clinical stage drug development company that develops novel class of living medicines for the treatment of rare and genetic metabolic diseases, by applying synthetic biology to probiotics. The company’s pipeline includes SYNB1020 a …
  • Zuivelcooperatie FrieslandCampina UA：企業の戦略的SWOT分析
    Zuivelcooperatie FrieslandCampina UA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Stealth BioTherapeutics Corp (MITO)：企業の財務・戦略的SWOT分析
    Stealth BioTherapeutics Corp (MITO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆